221 results
8-K
EX-99.3
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
on research and development and litigation; Expectations regarding the reimbursement environment for the Company’s products; The Company’s long-term strategy
8-K
EX-99.2
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
and development and litigation; Expectations regarding the reimbursement environment for the Company’s products; The Company’s long-term strategy
8-K
EX-99.1
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
distribution rights to a Collagen particulate xenograft product and regulatory and litigation expenses incurred relating to the FDA designation of one
8-K
EX-99.1
fyumnm8mpnnx 35s8q
28 Dec 23
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
4:30pm
8-K
EX-99.1
9h3m9lpfc cz
5 Jul 23
MIMEDX Appoints Doug Rice as Chief Financial Officer
9:02am
8-K
EX-99.2
b6lrlnan
20 Jun 23
Departure of Directors or Certain Officers
4:03pm
8-K
EX-10.1
ucc2 rbau
14 Jun 23
Departure of Directors or Certain Officers
4:23pm
8-K
EX-99.2
89iew4fd449
2 May 23
MIMEDX Announces First Quarter 2023 Operating and Financial Results
4:06pm